Mr. Jabbour is a co-founder and President of Matinas BioPharma Holdings, Inc., (NYSE: MTNB) a clinical stage biopharmaceutical company focused on the development of cochleate technologies to deliver potent drugs to treat Superbugs. Drug resistant infections (“Superbugs”) are an impeding global epidemic expected to kill 10+ million persons by 2050 according to the World Health Organization (e.g. more deaths than caused by cancer today).
Matinas’ lead drug candidate, MAT 2203, is being financed and developed in collaboration with the U.S. National Institute of Allergies and Infectious Diseases (NIAIB).
Previously, Mr. Jabbour served as Executive Vice President and General Counsel of MediMedia, a diversified health care services company; Senior Vice President and Head of Global Legal Affairs at Wockhardt Limited, a global pharmaceutical and biotechnology company; and as Commercial Counsel to Reliant Pharmaceuticals, a subsidiary of GlaxoSmithKline.
He received his J.D. from Seton Hall University School of Law.